Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Testis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Testis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-021898-36 Sponsor Protocol Number: INT 38/10 Start Date*: 2010-10-20
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment.
    Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043302 LLT
    9.1 10061378 LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004075-23 Sponsor Protocol Number: SWENOTECA-ABC-1 Start Date*: 2015-02-26
    Sponsor Name:St Olavs University Hospital
    Full Title: A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer
    Medical condition: Stage I, Seminomatous, Testicular cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10043322 Testicular neoplasms malignant HLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004458-27 Sponsor Protocol Number: Krypto-3 Start Date*: 2021-01-21
    Sponsor Name:Rigshospitalet
    Full Title: Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur.
    Medical condition: Cryptorchidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10056600 Cryptorchidism LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002945-41 Sponsor Protocol Number: 78464317 Start Date*: 2020-09-24
    Sponsor Name:Lone Nikolajsen
    Full Title: The use of intraoperative methadone in children undergoing open urological surgery
    Medical condition: Postoperative pain in children undergoing open urological surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10031063 Orchiopexy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10011498 Cryptorchism PT
    20.0 100000004856 10022017 Inguinal hernias HLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020488 Hydrocele PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000894-19 Sponsor Protocol Number: CA209-647 Start Date*: 2016-09-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
    Medical condition: Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036685 Primary central nervous system lymphoma LLT
    20.0 100000004864 10043302 Testicular cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005481-18 Sponsor Protocol Number: BNT142-01 Start Date*: 2022-04-28
    Sponsor Name:BioNTech SE
    Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol...
    Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004323-20 Sponsor Protocol Number: BNT211-01 Start Date*: 2020-06-30
    Sponsor Name:BioNTech Cell & Gene Therapies GmbH
    Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-...
    Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046766 Uterine cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004630-38 Sponsor Protocol Number: HydroceleAlkScler Start Date*: 2021-05-20
    Sponsor Name:Region Jämtland/Härjedalen
    Full Title: Sclerotherapy for hydro and spermatoceles with 99.5% Ethanol, an open clinical multicenter dose escalation study, phase 2
    Medical condition: Hydrocele and Spermatocele
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020488 Hydrocele PT
    20.0 10038604 - Reproductive system and breast disorders 10041490 Spermatocele PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000731-28 Sponsor Protocol Number: EORTC 30983 Start Date*: 2006-03-23
    Sponsor Name:EORTC
    Full Title: A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer
    Medical condition: Patients with Intermediate Prognosis Germ cell Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004508-36 Sponsor Protocol Number: FM-12-GCT01 Start Date*: 2013-05-04
    Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori
    Full Title: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial
    Medical condition: Patients with histologically-confirmed germ-cell cancer with exclusive or prevalent CD30-positive embryonal carcinoma component
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004667-61 Sponsor Protocol Number: SUITE - CUOG-TE 05 Start Date*: 2007-02-22
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study
    Medical condition: germ cell cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 Testicular germ cell cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005607-13 Sponsor Protocol Number: NN8640-4467 Start Date*: 2022-07-15
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ...
    Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    23.0 100000004859 10066333 Idiopathic short stature LLT
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006295-29 Sponsor Protocol Number: ICR-CTSU/2008/10019 Start Date*: 2009-08-20
    Sponsor Name:The Institute of Cancer Research [...]
    1. The Institute of Cancer Research
    2. University Hospital Birmingham NHS Foundation Trust
    Full Title: A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT)
    Medical condition: Patients with newly diagnosed NSGCTT or mixed GCT (MGCT) with vascular invasion and stage 1 disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029557 Non-seminoma testicular cancer LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-004632-38 Sponsor Protocol Number: GCTSK005 Start Date*: 2017-11-09
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.
    Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039956 Seminoma PT
    20.0 100000021189 10029557 Non-seminoma testicular cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004450-28 Sponsor Protocol Number: T109/2012 Start Date*: 2013-02-18
    Sponsor Name:University of Turku [...]
    1. University of Turku
    2. Turku University Hospital
    Full Title: Effect of chemotherapy on endothelial function in patients with testicular cancer
    Medical condition: Testicular cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10043362 Testis neoplasm malignant LLT
    14.1 100000004864 10043321 Testicular germ cell cancer NOS LLT
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004418-32 Sponsor Protocol Number: TestisCAB Start Date*: 2016-03-16
    Sponsor Name:Oslo University Hospital - Cancer Department
    Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer.
    Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed) DK (Completed) SE (Ongoing) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005223-18 Sponsor Protocol Number: NRA6280030 Start Date*: 2005-05-12
    Sponsor Name:Childrens´ Hospital Erlangen
    Full Title: Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study
    Medical condition: Genotropin®) is approved for treatment of short statured children in specific indications. A benefit can also be achieved in other pathological conditions that lead to growth retardation. Because ...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000286-36 Sponsor Protocol Number: IGR2012/1950 Start Date*: 2014-04-02
    Sponsor Name:Gustave Roussy
    Full Title: A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors
    Medical condition: patients with pre-treated metastatic and /or primary mediastinal non-seminomatous germ-cell tumors
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001507-19 Sponsor Protocol Number: 04/5/025 Start Date*: 2005-05-22
    Sponsor Name:National Children's Hospital & Trinity College Dublin
    Full Title: Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth.
    Medical condition: Short stature in children born small for gestational age without catch up growth
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005840-87 Sponsor Protocol Number: SAKK0110 Start Date*: 2013-10-10
    Sponsor Name:Swiss Group for Clinical Cancer Research SAKK
    Full Title: Carboplatin chemotherapy and involved node radiotherapy in stage IIA/B seminoma
    Medical condition: Patients with seminoma stage IIA/B, after orchidectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 17:21:39 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA